UPDATE 1-Lonza extends supply deal with Bristol-Myers

(Adds more details)

ZURICH, March 12 (Reuters) - Swiss pharmaceuticals industry supplier Lonza (LONN.VX) said on Monday it had extended a supply agreement for the active ingredient of Bristol-Myers Squibb's (BMY.N) rheumatoid arthritis drug Orencia until the end of 2013.

The extension of the deal, for manufacturing the biologic agent abatacept at Portsmouth, New Hampshire, will give Bristol-Myers more production capacity for Orencia, Lonza said in a statement.

Orencia, given by intravenous infusion, was launched in the United States last year.

Lonza did not disclose financial details of the agreement.

((Reporting by Sam Cage,

Editing by Quentin Bryar

Email: zurich.newsroom@reuters.com

Reuters Messaging:

sam.cage.reuters.com@reuters.net

Telephone: +41 (0) 44 631 7457)) Keywords: LONZA BRISTOLMYERS/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL12252967